

Prepared on 4 April 2022

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of the ILP Sub-Fund and complements the Product Summary.
- It is important to read the Product Summary before deciding whether to purchase the ILP Sub-Fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP Sub-Fund if you do not understand it or are not comfortable with the accompanying risks.

**Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund
(invests in Franklin Biotechnology Discovery Fund A Acc SGD)**

Product Type	ILP Sub Fund ¹	Launch Date³	02 April 2012
Units in the ILP Sub-Fund are Excluded Investment Products²	No	Custodian	N.A.
		Depository	J.P. Morgan SE – Luxembourg Branch ^
Manager	<u>Management Company</u> Franklin Templeton International Services S.à r.l <u>Investment Manager</u> Franklin Advisers, Inc	Dealing Frequency	Every Business Day
		Expense Ratio for the financial year ended 30 June 2021	1.83%
Capital Guaranteed	No		
Name of Guarantor	N.A.		

SUB-FUND SUITABILITY

WHO IS THE SUB-FUND SUITABLE FOR?

The ILP Sub-Fund is only suitable for investors who:

- Seek capital appreciation;
- Seek a growth investment in equity securities in the biotechnology sector in the US and around the world; and
- Plan to hold their investment for the medium to long term.

The principal may be at risk.

Further Information

Refer to “Fund Information, Objectives and Investment Policies” of the Underlying Fund’s Luxembourg Prospectus for further information on Sub-Fund suitability.

KEY FEATURES OF THE SUB-FUND

WHAT ARE YOU INVESTING IN?

Refer to “Investment

¹ For ILP Sub-Funds that feed 100% into an underlying CIS fund, some of the information provided below could be similar to the underlying CIS fund.

² In order for units in the ILP Sub-Fund to be classified as Excluded Investment Products, the investment objectives and investment focus of the ILP Sub-Fund, and investment approach of the manager have to be stated in the product summary:

- (a) to invest only in deposits or other Excluded Investment Products; and
- (b) not to engage in securities lending or repurchase transactions for the ILP Sub-Fund.

The definition of “Excluded Investment Product” can be found in Annex 1 to the Notice on Recommendations on Investment Products [Notice No. FAA-N16] at <https://www.mas.gov.sg/regulation/notices/notice-faa-n16>.

³Launch date is based on ZURICH launch date on 02 April 2012.

<ul style="list-style-type: none"> You are investing in an ILP sub-fund that feeds 100% into the Underlying Fund, an open-ended collective investment scheme (constituted in Luxembourg as a UCITS that aims to provide you with capital appreciation by a growth investment in equity securities in the biotechnology sector in the US and around the world. 	Objective, Focus and Approach of the Funds” section of the Underlying Fund’s Singapore Prospectus for further information on features of Sub-Fund.
Investment Strategy	
<ul style="list-style-type: none"> The Underlying Fund will invest principally in equity securities of biotechnology companies and discovery research firms of any size located in the US and other countries. It may also invest in debt securities of any type of issuers worldwide. A biotechnology company is one that has at least 50% of its earnings coming from, or at least 50% of its net assets devoted to, biotechnology activities. The Underlying Fund will usually invest more in the US than in any other individual country although it may have more than 50% of its net assets in non-US securities. The Underlying Fund may invest in derivatives for the purposes of hedging and/or efficient portfolio management. 	Refer to “Investment Objective, Focus and Approach of Funds” section of the Underlying Fund’s Singapore Prospectus for further information on the investment strategy of the Sub-Fund.
Parties Involved	
<p>WHO ARE YOU INVESTING WITH?</p> <ul style="list-style-type: none"> The investment company of the Underlying Fund is Franklin Templeton Investment Funds. The investment manager of the Underlying Fund is Franklin Advisers, Inc. The management company of the Underlying Fund is Franklin Templeton International Services S.à r.l. The depository of the Underlying Fund is J.P. Morgan SE – Luxembourg Branch ^. The Singapore representative of the Underlying Fund is Templeton Asset Management Ltd. 	Refer to “Management and Administration” section of the Underlying Fund’s Singapore Prospectus for more information on the role and responsibilities of these entities.
KEY RISKS	
<p>WHAT ARE THE KEY RISKS OF THIS INVESTMENT?</p> <p>The value of the ILP Sub-Fund may rise or fall. The following key risk factors may cause you to lose some or all of your investment:</p>	Refer to the “Risk Factors” section of the Underlying Fund’s Singapore Prospectus and “Risk Considerations” section of the Underlying Fund’s Luxembourg Prospectus for further information on risks of Sub-Fund.
Market and Credit Risks	
<p>You may be exposed to Equity Market Risks</p> <ul style="list-style-type: none"> Your investments may be subject to significant price movements due to the impact of economic, political, market, and issuer -specific factors. 	
Liquidity Risks	
<p>The ILP Sub-Fund is not listed on the Singapore Exchange and you can redeem only on Business Days through Singapore Life Ltd. In respect of Singapore investors, there is no secondary market for the ILP Sub-Fund.</p>	

Product-Specific Risks

You are exposed to risk associated with the biotechnology sectors.

- The Underlying Fund tends to invest in the biotechnology sectors. These sectors may present greater risk and higher volatility than investment in a broader range of securities covering different economic sectors and tend to be subject to greater government regulation, which could have an adverse impact on the Underlying Fund's performance.

Your investments are exposed to concentration risk.

- The Underlying Fund invests primarily in a single sector, market or region, and as a result is subject to higher concentration risk and potentially greater volatility compared to Underlying Funds following a more diversified policy.

Your investments exposed to risks associated with small to mid-sized companies.

- The Underlying Fund will invest in small to mid-sized companies, which tend to have less liquidity and be more sensitive to changes in economic conditions and interest rates than larger, more recognized companies. As a result, the stock prices of small to mid-sized companies tend to fluctuate up and down more than those of larger companies.

Your investments are exposed to growth stocks risk.

- Growth stocks may be more expensive, relative to their earnings, than the market in general and their price may be more sensitive to market sentiment, especially upon publication of quarterly financial results.

FEES AND CHARGES

WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?

Payable directly by you

There is currently no Switching Fee for fund switching. Sales and/or Surrender Charges may be applicable as described in the relevant Product Summary. However, Singapore Life Ltd. reserves the right to review and amend the Fees and Charges.

Payable by the Underlying Fund from invested proceeds

Other fees and charges may be payable by the Underlying Fund, as described in the Underlying Fund's Prospectus.

Refer to the Fees and Charges Section of the Product Summary for further information of the Fees and Charges of this investment.

Annual Management Charge	1.50% p.a.
Annual Custodian Fee	0.01% to 0.14% p.a. or higher if the Underlying Fund's investment objective and policy provides for investments in equity securities of issuers in developing countries.
Annual Admin Fee	Max. 0.20% p.a. plus additional amount per Investor Holding over one-year period.
Annual Investment Management Fee	
(a) Retained by Management Company	(a) 52.5% to 100% of Annual Investment Fee
(b) Paid by Management Company to financial adviser or distributor (trailer fee)	(b) 0% to 47.50% of Annual Investment Fee

VALUATIONS AND EXITING FROM THIS INVESTMENT

HOW OFTEN ARE VALUATIONS AVAILABLE?

All ILP Sub-Funds will be priced based on the frequency of the fund manager’s pricing. The fund prices are updated daily and are available at Singapore Life Ltd.’s website at www.singlife.com

HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?

- You can exit the ILP Sub-Fund by submitting a request for withdrawal or fund switching (i.e. switches) to Singapore Life Ltd.
- If your Policy is newly incepted, you may cancel the Policy by giving us written notice of cancellation provided that such notice of cancellation is received by Singapore Life Ltd. at its Registered Office within the free-look period, which is fourteen (14) days from the date on which you receive the Policy.
- Upon cancellation of the Policy, Singapore Life Ltd. will refund the premiums you paid (without interest) after deducting the expenses incurred in issuing the Policy. The refund will be made after we receive the original Policy for cancellation.
- If there has been a decline in the market value, we will deduct the amount necessary to reflect the change in market value. If there has been an increase in the market value following the date Singapore Life Ltd. accepts your request to cancel the Policy, we will not pay you for such increase or any gain.
- For subsequent withdrawal/surrender or fund switching, transaction requests will need to be received and accepted by Singapore Life Ltd.:
 - (a) before 12 noon (Singapore time) on a Business Day will be processed according to the Unit Prices of the relevant Funds and the exchange rates (if applicable) prevailing on the next appropriate Fund Valuation Date following the day Singapore Life Ltd. has accepted the request.
 - (b) after 12 noon (Singapore time) on a Business Day or on a non-business day will be considered as if received before 12 noon (Singapore time) on the following business day.
- The ILP Sub-Fund will have a single “dealing” price used for all switches and withdrawals/surrenders. There is no bid/offer spread.
- All ILP Sub-Funds will be priced based on the frequency of the fund manager’s pricing policy. As Units are cancelled using a forward price, the unit price for all switching and withdrawal of units will not be available at the time of receiving your application.
- This cut-off time stated is correct as at the time of print. Singapore Life Ltd. reserves the right to change the cut-off time by giving you thirty (30) days’ prior notice or any such shorter period of notice as Singapore Life Ltd. may agree with the relevant authorities.
- The Withdrawal Amount you will receive as part of a subsequent withdrawal is illustrated as follows:
 For a partial withdrawal request of 1000 units of an investment-linked fund.
 - Assuming the unit price of the fund is S\$1.50:
 The amount payable to the policyholder will be S\$1500, which is calculated as 1000 units x S\$1.50.

Refer to the Pricing of Units & Dealing Deadline, Fund Switching, Withdrawal/Surrender and Free Look sections of the Product Summary for further information.

CONTACT INFORMATION

HOW DO YOU CONTACT US?

Singapore Life Ltd.
 4 Shenton Way, #01-01 SGX Centre 2, Singapore 068807
Email: cs_life@singlife.com
Website: www.singlife.com

Hotline: 6827 9933

APPENDIX: GLOSSARY OF TERMS

Dealing Day:	means each day which is both a Valuation Day and a Singapore Business Day, or otherwise as the Directors may from time to time determine.
NAV:	means Net Asset Value.
Singapore Business Day:	means a day (except Saturdays, Sundays and public holidays) on which commercial banks are open for business in Singapore.
UCITS:	means an undertaking for collective investment in transfer securities.
Underlying Fund:	Franklin Biotechnology Discovery Fund A Acc SGD.
Valuation Day:	means any day on which the New York Stock Exchange (NYSE) is open or any full day on which banks in Luxembourg are open for normal business (other than during a suspension of normal dealing).
^:	With effect on or around 22 January 2022 (“Merger Date”), J.P Morgan Bank Luxembourg S.A. will merge into J.P. Morgan AG which at the same time will change its legal form from a German Stock Corporation to a European Company, being J.P. Morgan SE. From the Merger Date, J.P. Morgan SE will, as legal successor of J.P. Morgan Bank Luxembourg S.A., continue to act as Depositary through its Luxembourg Branch.